Cover Image
市場調查報告書

Xolair(氣喘):市場預測與分析

Xolair (Asthma) - Forecast and Market Analysis to 2023

出版商 GlobalData 商品編碼 316080
出版日期 內容資訊 英文 52 Pages
訂單完成後即時交付
價格
Back to Top
Xolair(氣喘):市場預測與分析 Xolair (Asthma) - Forecast and Market Analysis to 2023
出版日期: 2014年08月31日 內容資訊: 英文 52 Pages
簡介

Roche·Genentech·Novartis三家公司所開發的Xolair(Omalizumab)是目前唯一通過FDA(美國食品藥物管理局)認證的治療氣喘用生物醫藥品。這個藥劑藉由基因改造型人體化單株抗體(mAb),以與FceRI相同程度的親和性和IgE(免疫球蛋白)結合·中和。由於Omalizumab和IgE的複合體不會與細胞膜受體結合·運作,具有妨礙效應細胞辦視過敏原(肥胖細胞,嗜酸性粒細胞,巨噬細胞等)的效果。

本報告提供氣喘治療藥之一──Xolair的全球市場相關分析,提供氣喘概要和治療方法,競爭的企業、藥品概要,市場競爭概況,Xolair的商品資訊(特色·功效·安全性等),全球主要國家的市場銷售額預測(今後10年份)等調查,並將結果概述為以下內容。

第1章 目錄

第2章 簡介

  • 分析的背景情況
  • 相關報告
  • 預定公開的相關報告書

第3章 疾病概要

  • 病因與病理學
    • 病因
    • 病理學
    • 預後
    • 生活品質(QoL)
  • 症狀

第4章 疾病管理

  • 診斷及治療概要
    • 診斷
    • 治療指南,臨床診療及代表性的處方藥
    • 臨床診療

第5章 競爭評估

  • 概要
  • 策略性競爭評估

第6章 Xolair(Omalizumab)

  • 概要
  • 有效性
  • 安全性
  • SWOT分析
  • 預測

第7章 附錄

圖表一覽

目錄

GlobalData has released its new PharmaPoint Drug Evaluation report, "Xolair (Asthma) - Forecast and Market Analysis to 2023". The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious standard therapies, such as short-acting beta-agonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and has also been facing increasing generic competition. However, the launch of seven novel targeted biologic agents and once-daily ICS and ICS/LABA therapies delivered by the next-generation inhalers will strongly drive the market growth over the next 10 years. The biologic agents will not only reshape the market growth, but will also mark the beginning of a new era of a personalized approach to asthma treatment. The realization that asthma is a very heterogeneous disease is highly reflected in the rich assortment of these targeted therapies in the late-stage pipeline.

Roche/Genentech/Novartis' Xolair (omalizumab) is currently the only FDA-approved biologic used in the treatment of asthma. This drug is a recombinant humanized mAb that binds and neutralizes IgE with the same high affinity as its cognate receptor, FceRI. The omalizumab-IgE complexes are unable to bind and activate cell membrane-bound receptor, thus preventing the recognition of the allergen by effector cells, including mast cells, eosinophils, and macrophages.

Scope

  • Overview of Asthma, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Xolair including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Xolair for the top eight countries from 2013 to 2023.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Asthma
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Xolair performance
  • Obtain sales forecast for Xolair from 2013-2023 in top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and Australia)

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
    • 3.1.3. Prognosis
    • 3.1.4. Quality of Life
  • 3.2. Symptoms

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Diagnosis
    • 4.1.2. Treatment Guidelines, Clinical Practice, and Leading Prescribed Drugs
    • 4.1.3. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment

6. Xolair (omalizumab)

  • 6.1. Overview
  • 6.2. Efficacy
  • 6.3. Safety

6.4. SWOT Analysis

  • 6.5. Forecast

7. Appendix

  • 7.1. Bibliography
  • 7.2. Abbreviations
  • 7.3. Methodology
  • 7.4. Forecasting Methodology
    • 7.4.1. Diagnosed Asthma Patients
    • 7.4.2. Percent Drug-Treated Patients
    • 7.4.3. General Pricing Assumptions
    • 7.4.4. Individual Drug Assumptions
    • 7.4.5. Generic Erosion
  • 7.5. Physicians and Specialists Included in This Study
  • 7.6. About the Authors
    • 7.6.1. Author
    • 7.6.2. Author/Reviewer
    • 7.6.3. Reviewer
    • 7.6.4. Global Head of Healthcare
  • 7.7. About GlobalData
  • 7.8. Disclaimer

List of Tables

  • Table 1: Symptoms of Asthma
  • Table 2: Treatment Guidelines for Asthma by Country
  • Table 3: Most Prescribed Drugs for Asthma by Class and Disease Severity in the Global Markets, 2013
  • Table 4: Dosing of Common ICSs for Adult Asthma Therapy to Achieve Equivalent Therapeutic Potency
  • Table 5: Recommended Low Daily Dose of ICSs in Children with Asthma Under Five Years of Age
  • Table 6: Leading Treatments for Asthma, 2014
  • Table 7: Product Profile - Xolair
  • Table 8: Efficacy - Xolair Versus Placebo
  • Table 9: Xolair SWOT Analysis, 2014
  • Table 10: Global Sales Forecast ($) for Xolair, 2013-2023
  • Table 11: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1:Stepwise Disease Management Approach for Asthma in Adults
  • Figure 2: Stepwise Disease Management Approach for Asthma in Children Age Five and Younger
Back to Top